melatonin has been researched along with Kidney Neoplasms in 18 studies
Kidney Neoplasms: Tumors or cancers of the KIDNEY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In particular, the association with the pineal neurohormone melatonin (MLT) has been shown to cause tumour regressions in neoplasms that are generally non-responsive to IL-2 alone." | 9.07 | A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. ( Aldeghi, R; Ardizzoia, A; Barni, S; Brivio, F; Lissoni, P; Rescaldani, R; Ricci, G; Rovelli, F; Tancini, G; Tisi, E, 1994) |
| " In particular, the association with the pineal neurohormone melatonin (MLT) has been shown to cause tumour regressions in neoplasms that are generally non-responsive to IL-2 alone." | 5.07 | A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. ( Aldeghi, R; Ardizzoia, A; Barni, S; Brivio, F; Lissoni, P; Rescaldani, R; Ricci, G; Rovelli, F; Tancini, G; Tisi, E, 1994) |
| "Melatonin is a serotonin-derived pineal gland hormone with many biological functions like regulating the sleep-wake cycle, circadian rhythm, menstrual cycle, aging, immunity, and antioxidants." | 3.01 | Exploring the Mechanical Perspective of a New Anti-Tumor Agent: Melatonin. ( Almalki, WH; Chellappan, DK; Dua, K; Fuloria, NK; Fuloria, S; Gupta, G; Haniffa, SM; Jha, NK; Negi, P; Priya, S; Rohilla, S; Sekar, M; Singh, M; Singh, SK; Subramaniyan, V, 2023) |
| "Melatonin was given orally at 20 mg/day in the evening for at least 2 months." | 2.70 | Anti-angiogenic activity of melatonin in advanced cancer patients. ( Bucovec, R; Conti, A; Lissoni, P; Maestroni, GJ; Malugani, F; Rovelli, F, 2001) |
| "Melatonin plays a role in cancer therapy due to its anti-tumor effects as well as by enhancing the efficacy of other drugs as an adjuvant." | 2.66 | Melatonin as a potential inhibitor of kidney cancer: A survey of the molecular processes. ( Asemi, Z; Hallajzadeh, J; Maleki Dana, P; Mansournia, MA; Reiter, RJ; Yousefi, B, 2020) |
| "Metabolic alteration drives renal cell carcinoma (RCC) development, while the impact of melatonin (MLT), a neurohormone secreted during darkness, on RCC cell growth and underlying mechanisms remains unclear." | 1.91 | Melatonin suppresses Akt/mTOR/S6K activity, induces cell apoptosis, and synergistically inhibits cell growth with sunitinib in renal carcinoma cells via reversing Warburg effect. ( Bai, JY; Chen, YH; Guo, P; Jiang, YF; Ma, JB; Wang, X; Xue, KH; Zhang, DZ; Zhu, ZJ, 2023) |
| "Cotreatment with melatonin (1mm) and TG (50nm) induced approximately 10-fold expression levels of CCAAT-enhancer-binding proteins homologous protein (CHOP) compared with that of TG (50nm) alone." | 1.38 | Melatonin enhances thapsigargin-induced apoptosis through reactive oxygen species-mediated upregulation of CCAAT-enhancer-binding protein homologous protein in human renal cancer cells. ( Kim, HS; Kwon, TK; Min, KJ; Park, EJ, 2012) |
| "Co-treatment with melatonin and kahweol induced up-regulation of p53-upregulated modulator of apoptosis (PUMA) while down-regulation of PUMA expression using small interfering RNAs attenuated melatonin plus kahweol-induced apoptosis." | 1.37 | Melatonin sensitizes Caki renal cancer cells to kahweol-induced apoptosis through CHOP-mediated up-regulation of PUMA. ( Kwon, TK; Park, JW; Um, HJ, 2011) |
| "Melatonin is a well-known antioxidant, free radical scavenger and oncostatic agent." | 1.31 | Comparison of the protective effect of melatonin with other antioxidants in the hamster kidney model of estradiol-induced DNA damage. ( Cabrera, J; Garcia, JJ; Karbownik, M; Reiter, RJ, 2001) |
| "The study was performed on metastatic renal cell cancer patients." | 1.30 | Immunomodulatory effects of IL-12 in relation to the pineal endocrine function in metastatic cancer patients. ( Fumagalli, L; Giani, L; Lissoni, P; Mandalà, M; Rovelli, F, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 5 (27.78) | 2.80 |
| Authors | Studies |
|---|---|
| Rohilla, S | 1 |
| Singh, M | 1 |
| Priya, S | 1 |
| Almalki, WH | 1 |
| Haniffa, SM | 1 |
| Subramaniyan, V | 1 |
| Fuloria, S | 1 |
| Fuloria, NK | 1 |
| Sekar, M | 1 |
| Singh, SK | 1 |
| Jha, NK | 1 |
| Chellappan, DK | 1 |
| Negi, P | 1 |
| Dua, K | 1 |
| Gupta, G | 1 |
| Jiang, A | 1 |
| Cai, C | 1 |
| Yang, Y | 1 |
| Cui, Y | 1 |
| Liu, W | 1 |
| Pang, Q | 1 |
| Wu, Z | 1 |
| Liu, B | 1 |
| Qu, L | 1 |
| Luo, P | 1 |
| Wang, A | 1 |
| Wang, L | 1 |
| Xue, KH | 1 |
| Jiang, YF | 1 |
| Bai, JY | 1 |
| Zhang, DZ | 1 |
| Chen, YH | 1 |
| Ma, JB | 1 |
| Zhu, ZJ | 1 |
| Wang, X | 1 |
| Guo, P | 1 |
| Wen, YC | 1 |
| Lin, YW | 2 |
| Chu, CY | 2 |
| Yang, YC | 2 |
| Yang, SF | 2 |
| Liu, YF | 1 |
| Hsiao, M | 2 |
| Lee, WJ | 2 |
| Chien, MH | 2 |
| Maleki Dana, P | 1 |
| Reiter, RJ | 2 |
| Hallajzadeh, J | 1 |
| Asemi, Z | 1 |
| Mansournia, MA | 1 |
| Yousefi, B | 1 |
| Lee, LM | 1 |
| Tan, P | 1 |
| Chen, WY | 1 |
| Um, HJ | 1 |
| Park, JW | 1 |
| Kwon, TK | 2 |
| Min, KJ | 1 |
| Kim, HS | 1 |
| Park, EJ | 1 |
| Kim, KJ | 1 |
| Choi, JS | 1 |
| Kang, I | 1 |
| Kim, KW | 1 |
| Jeong, CH | 1 |
| Jeong, JW | 1 |
| Lissoni, P | 5 |
| Malugani, F | 2 |
| Malysheva, O | 1 |
| Kozlov, V | 1 |
| Laudon, M | 1 |
| Conti, A | 2 |
| Maestroni, G | 1 |
| Song, Y | 1 |
| Tam, PC | 1 |
| Poon, AM | 1 |
| Brown, GM | 1 |
| Pang, SF | 1 |
| Neri, B | 1 |
| Fiorelli, C | 1 |
| Moroni, F | 1 |
| Nicita, G | 1 |
| Paoletti, MC | 1 |
| Ponchietti, R | 1 |
| Raugei, A | 1 |
| Santoni, G | 1 |
| Trippitelli, A | 1 |
| Grechi, G | 1 |
| Barni, S | 1 |
| Tancini, G | 1 |
| Ardizzoia, A | 1 |
| Ricci, G | 1 |
| Aldeghi, R | 1 |
| Brivio, F | 2 |
| Tisi, E | 1 |
| Rovelli, F | 3 |
| Rescaldani, R | 1 |
| Taverna, G | 1 |
| Trinchieri, A | 1 |
| Mandressi, A | 1 |
| Del Nero, A | 1 |
| Mangiarotti, B | 1 |
| Antonelli, D | 1 |
| Chisena, S | 1 |
| Pisani, E | 1 |
| Mandalà, M | 2 |
| Giani, L | 1 |
| Fumagalli, L | 1 |
| Karbownik, M | 1 |
| Cabrera, J | 1 |
| Garcia, JJ | 1 |
| Bucovec, R | 1 |
| Maestroni, GJ | 1 |
2 reviews available for melatonin and Kidney Neoplasms
| Article | Year |
|---|---|
Exploring the Mechanical Perspective of a New Anti-Tumor Agent: Melatonin.
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Kidney Neoplasms; Lung Neoplasms; | 2023 |
Melatonin as a potential inhibitor of kidney cancer: A survey of the molecular processes.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antioxidants; Humans; Kidney Neoplasms; Mel | 2020 |
5 trials available for melatonin and Kidney Neoplasms
| Article | Year |
|---|---|
Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Agents; Carcinoma, Neuroendocrine; Carcinoma, Renal Cel | 2002 |
Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. A phase II study.
Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Humans; Interferon-alpha; Kidney Neoplasms; Male; Melato | 1994 |
A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colorec | 1994 |
Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin.
Topics: Adjuvants, Immunologic; Adult; Analgesics, Opioid; Carcinoma, Renal Cell; Female; Follow-Up Studies; | 2000 |
Anti-angiogenic activity of melatonin in advanced cancer patients.
Topics: Adult; Aged; Bone Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; C | 2001 |
11 other studies available for melatonin and Kidney Neoplasms
| Article | Year |
|---|---|
Deciphering the Role of Melatonin-Related Signatures in Tumor Immunity and the Prognosis of Clear Cell Renal Cell Carcinoma.
Topics: Algorithms; Carcinoma, Renal Cell; DNA Copy Number Variations; Humans; Kidney Neoplasms; Melatonin; | 2023 |
Melatonin suppresses Akt/mTOR/S6K activity, induces cell apoptosis, and synergistically inhibits cell growth with sunitinib in renal carcinoma cells via reversing Warburg effect.
Topics: Antioxidants; Apoptosis; Carcinoma, Renal Cell; Chromatography, Liquid; Humans; Kidney Neoplasms; Me | 2023 |
Melatonin-triggered post-transcriptional and post-translational modifications of ADAMTS1 coordinately retard tumorigenesis and metastasis of renal cell carcinoma.
Topics: ADAMTS1 Protein; Animals; Carcinogenesis; Carcinoma, Renal Cell; Cell Line, Tumor; Humans; Kidney Ne | 2020 |
Melatonin inhibits MMP-9 transactivation and renal cell carcinoma metastasis by suppressing Akt-MAPKs pathway and NF-κB DNA-binding activity.
Topics: Animals; Carcinoma, Renal Cell; DNA, Neoplasm; Gene Expression Regulation, Enzymologic; Gene Express | 2016 |
Melatonin sensitizes Caki renal cancer cells to kahweol-induced apoptosis through CHOP-mediated up-regulation of PUMA.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Cell Line; Cell Line, Tumor; Diterpenes | 2011 |
Melatonin enhances thapsigargin-induced apoptosis through reactive oxygen species-mediated upregulation of CCAAT-enhancer-binding protein homologous protein in human renal cancer cells.
Topics: Antioxidants; Apoptosis; Cell Line, Tumor; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic | 2012 |
Melatonin suppresses tumor progression by reducing angiogenesis stimulated by HIF-1 in a mouse tumor model.
Topics: Animals; Cell Line, Tumor; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney Neoplasms; Male; Melato | 2013 |
2-[125I]iodomelatonin-binding sites in the human kidney and the effect of guanosine 5'-O-(3-thiotriphosphate).
Topics: Adult; Aged; Autoradiography; Binding Sites; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Fe | 1995 |
Variation in nocturnal urinary excretion of melatonin in a group of patients older than 55 years suffering from urogenital tract disorders.
Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Circadian Rhythm; Fema | 1997 |
Immunomodulatory effects of IL-12 in relation to the pineal endocrine function in metastatic cancer patients.
Topics: Adjuvants, Immunologic; Carcinoma, Renal Cell; Humans; Immunity, Innate; Immunotherapy; Inflammation | 1998 |
Comparison of the protective effect of melatonin with other antioxidants in the hamster kidney model of estradiol-induced DNA damage.
Topics: Animals; Antioxidants; Cricetinae; DNA Damage; Estradiol; Kidney; Kidney Neoplasms; Melatonin; Mesoc | 2001 |